Home / 2021 / June / 14

Daily Archives: June 14, 2021

SNOMED International identifies the benefits of using SNOMED CT for its broad range of stakeholders in new report

London, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) — SNOMED International is pleased to announce the launch of a new report that details the value each of its many stakeholder groups can experience by implementing SNOMED CT, the most comprehensive global language for health terms. This report builds on the work captured in a series of videos completed in 2020 in which a New Zealand health board highlights the advances it has made in realizing its vision of a connected, integrated system by using SNOMED CT.

The report, titled SNOMED CT: Articulating Stakeholder Value, was developed over the past year as part of our efforts to meet our 2020-2025 Strategy commitments and to realize our vision of better health and improved patient outcomes worldwide.

It identifies where and how SNOMED CT is used, providing an end-to-end perspective of the entire universe of SNOMED CT users, including Members, policy makers, care providers, patients and citizens, researchers and knowledge producers, implementers, vendors and collaboration partners, and expands and extends our existing value propositions to each of those groups. It also lays out the pathway to realizing the full value of SNOMED CT when embedded in a clinical information system, a health data and analytics platform or an interoperability solution.

“There has been enormous evolution in the SNOMED CT product and community since the organization came into being,” states Don Sweete, CEO of SNOMED International. “As the organization and our community have evolved, so, too, has the value that the product and its resources offer healthcare systems and stakeholders worldwide.” Don also noted, “As a core clinical reference terminology that is unchallenged in terms of its clinical breadth and depth, our renewed value propositions mirror the evolution of our stakeholders in their past, present and future use of SNOMED CT.”

Based on the Delone and McLean IS Success Framework as the theoretical underpinning for the development of these segmented value propositions, the report demonstrates the role of SNOMED CT as a critical component of the entire ecosystem of clinical terminologies and the importance of collaboration among the sponsors of those terminologies.

It also provides government decision-makers with a clear understanding of how their investments in SNOMED CT translate into positive outcomes for the health of their nation’s citizens.

Highlights of the benefits by stakeholder groups

  • Policymakers are more informed when making policy and management decisions, accelerating data-driven analytics and decision-making processes
  • Members can ensure that high-quality clinical information is available to stakeholders within their nations
  • Collaboration Partners contribute their best-in-class clinical knowledge to SNOMED CT to ensure its clinical integrity and create the one language of health
  • Researchers and Knowledge Producers can accelerate data, information, evidence and knowledge creation, supporting a wide range of analytics and research to benefit the decision-making of policymakers and healthcare stakeholders
  • Implementers can collect data once and reuse it for a diverse range of clinical, management and research purposes to support a broad range of health stakeholders
  • Vendors can open up markets globally and expand market share by enhancing the information quality of their products, using a global standard used in over 80 countries
  • Care Providers can improve patient outcomes by being knowledgeable about their patient’s health and options for care, achieving a more informed and collaborative relationship when making critical care decisions
  • Patients/Citizens can control their own health information and be knowledgeable about their health and self-care options

Over the coming months, SNOMED International will build on this work with the release of an in-depth SNOMED CT Case for Investment, supported by economic benefits modeling and data-driven exemplar case studies of SNOMED CT use.

To read the report, Articulating Stakeholder Value, visit snomed.org/value.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

Media Inquiries

Kelly Kuru

Chief Communications Officer

[email protected]


Kelly Kuru
SNOMED International
[email protected]snomed.org

First Advantage Announces Launch of Initial Public Offering

ATLANTA, June 14, 2021 (GLOBE NEWSWIRE) — First Advantage Corporation, a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital, today announced the launch of the initial public offering of 21,250,000 shares of its common stock, of which 17,750,000 shares of common stock will be sold by First Advantage and 3,500,000 shares of common stock will be sold by certain existing stockholders of First Advantage. First Advantage and the selling stockholders expect to grant the underwriters in the offering a 30-day option to purchase up to an additional 3,187,500 shares of common stock, of which, up to 2,662,500 shares of common stock would be sold by First Advantage and up to 525,000 shares of common stock would be sold by certain existing stockholders of First Advantage. The estimated initial public offering price is between $13.00 and $15.00 per share. First Advantage has applied to list its shares on the Nasdaq Global Select Market under the symbol “FA”.

Barclays, BofA Securities and J.P. Morgan will act as lead bookrunners for the proposed offering. Citigroup, Evercore ISI, Jefferies, RBC Capital Markets, Stifel and HSBC will act as bookrunners, and Citizens Capital Markets, KKR Capital Markets LLC, MUFG, Loop Capital Markets, R. Seelaus & Co., LLC, Ramirez & Co., Inc. and Roberts & Ryan will act as co-managers for the proposed offering.

A registration statement on Form S-1 relating to the proposed offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering can be obtained from: Barclays Capital Inc., Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 888-603-5847, or by email at [email protected]com; BofA Securities, Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina, 28255-0001, by email at [email protected]com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at [email protected]com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include any statements regarding the commencement of trading of First Advantage’s common stock on the Nasdaq Global Select Market. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under “Risk Factors” under First Advantage’s registration statement relating to the offering. Except as required by law, First Advantage has no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

About First Advantage

First Advantage is a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital. The company delivers innovative solutions and insights that help customers manage risk and hire the best talent. Enabled by its proprietary technology platform, First Advantage’s products and solutions help companies protect their brands and provide safe environments for their customers and their most important resources: employees, contractors, contingent workers, tenants and drivers. Headquartered in Atlanta, Georgia, First Advantage has offices in North America, Europe, Asia and the Middle East.

Media Contact:

Elisabeth Warrick
First Advantage
[email protected]
(888) 314-9761

Jeanne Achille
The Devon Group
[email protected]
+1-732-706-0123, ext. 700

A2 Global Risk publishes new report assessing the investment risks associated with port infrastructure expansion in Sub-Saharan Africa

LONDON, June 14, 2021 (GLOBE NEWSWIRE) — London and Hong Kong-based risk management consultancy A2 Global Risk published a new report assessing the investment risks associated with port infrastructure expansion in Sub-Saharan Africa, against the backdrop of global geopolitical competition. The COVID-19 pandemic and associated restrictions on travel and operations caused unprecedented disruption to international trade and highlighted the risks linked with ageing port infrastructure and regional bottlenecks.

Cognisant of such risks, African governments are actively seeking to expand their infrastructure and trade provisions to reduce non-tariff barriers, as part of their efforts to modernise their trade infrastructure, such as airports, seaports, roads, and internet access. International actors active in this space are ramping up their competition for market access amid mounting trade and geopolitical tensions globally.

In Africa, traditional global powers such as France and the European Union on one hand, and China on the other, have for years competed over lucrative port expansion and management contracts. But both Western and Chinese companies have been accused of abuses and neo-colonialism. A growing number of Middle Eastern countries, led by the United Arab Emirates as well as Turkey, is now providing a third alternative.

While this growing competition offers African countries new alternatives to choose from, which may in turn foster local agency, it also raises questions about responsible corporate actors and signals emerging political risks to companies with an established presence.

“Gulf countries, particularly Saudi Arabia and the UAE, have markedly increased their presence on the continent, particularly in the Horn of Africa, over the past decade,” says Senior Analyst for Sub-Saharan Africa Olivier Milland. “To a large extent this forms part of their strategic development plans to diversify economies and secure future food supplies. Meanwhile, efforts at home to attract foreign capital or entice companies to establish offices in the region means that corporate standards there need to be elevated to the same level as those in advanced economies, placing a greater compliance burden on Gulf-based companies if they are to maintain a competitive advantage.”

About A2 Global RIsk
A2 Global Risk is a political and security risk management consultancy headquartered in Hong Kong with offices throughout Asia-Pacific as well as London and Washington DC. We provide subscription-based Information Services platform and bespoke security risk management services across the globe to help companies understand their political environments and mitigate risk accordingly. For more information visit www.a2globalrisk.com.

Carolyn Taylor
Senior Editor
Tel: +44 203 102 4053
Email: [email protected]

Philips issues recall notification* to mitigate potential health risks related to the sound abatement foam component in certain sleep and respiratory care devices

une 14, 2021

  • Philips is initiating a voluntary recall notification* to ensure patient safety in consultation with regulatory agencies
  • Corrective actions include the deployment of updated instructions for use and a repair and replacement program for affected devices
  • Philips aims to address all affected devices within the scope of this correction as expeditiously as possible

Amsterdam, the Netherlands – Following the company update on April 26, 2021, Royal Philips (NYSE: PHG; AEX: PHIA) today provides an update on the recall notification* for specific Philips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP), and mechanical ventilator devices to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam component in these devices. The majority of the affected devices within the advised 5-year service life are in the first-generation DreamStation product family.

To date, Philips has produced millions of Bi-Level PAP, CPAP and mechanical ventilator devices using the PE-PUR sound abatement foam. Despite a low complaint rate (0.03% in 2020), Philips determined based on testing that there are possible risks to users related to this type of foam. The risks include that the PE-PUR foam may degrade into particles which may enter the device’s air pathway and be ingested or inhaled by the user, and the foam may off-gas certain chemicals. The foam degradation may be exacerbated by use of unapproved cleaning methods, such as ozone,** and high heat and high humidity environments may also contribute to foam degradation.

Therefore, Philips has decided to voluntarily issue a recall notification* to inform patients and customers of potential impacts on patient health and clinical use related to this issue, as well as instructions on actions to be taken.

“We deeply regret any concern and inconvenience that patients using the affected devices will experience because of the proactive measures we are announcing today to ensure patient safety,” said Frans van Houten, CEO of Royal Philips. “In consultation with the relevant regulatory agencies and in close collaboration with our customers and partners, we are working hard towards a resolution, which includes the deployment of the updated instructions for use and a comprehensive repair and replacement program for the affected devices. Patient safety is at the heart of everything we do at Philips.”

Recall notification* advise for patients and customers
Based on the latest analysis of potential health risks and out of an abundance of caution, the recall notification* advises patients and customers to take the following actions:

  • For patients using affected BiLevel PAP and CPAP devices: Discontinue use of your device and work with your physician or Durable Medical Equipment (DME) provider to determine the most appropriate options for continued treatment. To continue use of your device due to lack of alternatives, consult with your physician to determine if the benefit of continuing therapy with your device outweighs the risks identified in the recall notification.*
  • For patients using affected life-sustaining mechanical ventilator devices: Do not stop or alter your prescribed therapy until you have talked to your physician. Philips recognizes that alternate ventilator options for therapy may not exist or may be severely limited for patients who require a ventilator for life-sustaining therapy, or in cases where therapy disruption is unacceptable. In these situations, and at the discretion of the treating clinical team, the benefit of continued usage of these ventilator devices may outweigh the risks identified in the recall notification.*

Possible health risks
The company continues to monitor reports of potential safety issues as required by medical device regulations and laws in the markets in which it operates. To date, there have been no reports of death as a result of these issues. Philips has received reports of possible patient impact due to foam degradation. The potential risks of particulate exposure include headache, irritation, inflammation, respiratory issues, and possible toxic and carcinogenic effects. The potential risks of chemical exposure due to off-gassing include headache, irritation, hypersensitivity, nausea/vomiting, and possible toxic and carcinogenic effects. Philips has received no reports regarding patient impact related to chemical emissions.

Repair and replacement program
Philips is providing the relevant regulatory agencies with required information related to the launch and implementation of the projected correction. The company will replace the current sound abatement foam with a new material and has already begun the preparations, which include obtaining the relevant regulatory clearances. Philips aims to address all affected devices in scope of this correction as expeditiously as possible.

As part of the program, the first-generation DreamStation product families will be modified with a different sound abatement foam and shipped upon receipt of the required regulatory clearances. Philips’ recently launched next-generation CPAP platform, DreamStation 2, is not affected by the issue. To support the program, Philips is increasing the production of its DreamStation 2 CPAP devices, that are available in the US and selected countries in Europe.

In terms of the financial impact, Philips anticipates that the expected revenue headwinds in the Sleep & Respiratory Care business in 2021 will be compensated by the strength of the company’s other businesses. Therefore, the full year comparable sales growth and Adjusted EBITA margin guidance provided on April 26, 2021 remains unchanged.

The updated instructions for use of the affected devices have resulted in adjustments to and acceleration of the repair and replacement program, as well as intensified communication with customers and patients. This had led to an increase of EUR 250 million in the expected costs of the corrective actions on the installed base, in addition to the provision that the company recorded in the first quarter of 2021.

Additional information
For more information on the recall notification,* as well as instructions for customers, users and physicians, affected parties may contact their local Philips representative or visit www.philips.com/SRC-update.

*     This is a recall notification for the US only, and a field safety notice for the rest of the world
**   Potential Risks Associated With The Use of Ozone and Ultraviolet (UV) Light Products for Cleaning CPAP Machines and Accessories: FDA Safety Communication.

For media and investor questions, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: [email protected]

Leandro Mazzoni
Philips Investor Relations
Tel.: +31 20 59 77222
E-mail: [email protected]

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Agong congratulates Damok over victory in Spain

Yang di-Pertuan Agong Al-Sultan Abdullah Ri’ayatuddin Al-Mustafa Billah Shah today congratulated young Malaysian racer Syarifuddin Azman for emerging victorious at the FIM CEV Moto3 Race in Barcelona, Spain yesterday.

In a statement uploaded on Istana Negara’s Facebook page today, His Majesty expressed his happiness and pride over the success, which was also described as not only a historical feat for Malaysian motosport but one which garnered accolades for the country on the international stage.

Al-Sultan Abdullah described Syarifuddin’s achievement as very meaningful for Malaysia and an inspiration for the rider better known as Damok in his hunt for more success in the future.

“Syarifuddin’s outstanding achievement once again proves that Malaysia is capable of producing athletes and individuals of quality, calibre and of international standards.

“It also proves that with commitment, fighting spirit and hard work, Malaysians are able to compete and succeed at the international level,” the statement read.

Al-Sultan Abdullah hoped Syarifuddin’s success and fighting spirit will be a source of inspiration to fellow Malaysians, in particular athletes, to work hard and strive for success in their respective fields domestically or on the international stage.

“TheYang di-Pertuan Agong wished Syarifuddin all the best and prayed that he would be blessed with continued success and to keep on putting the country on the world stage with more victories,” the statement said.

The Selangor-born rider emerged victorious after crossing the chequered flag in 29 minutes and 32.553 seconds in the 74.5-kilometre race, beating Spaniards David Munoz Rodriguez and Jose Antonio Rueda Ruiz to second and third places respectively.

The 25 points from the win helped Syarifuddin climb up to sixth place in the world championship standings with 30 points after three races.

Source: BERNAMA News Agency

COVID: Workplace clusters contributing to rise in new clusters – Health DG

Clusters linked to workplaces continue to contribute to the rise of new clusters in the country, with 1,328 detected to date, with 147,040 COVID-19 positive cases among the clusters, disclosed Health director-general, Tan Sri Dr Noor Hisham Abdullah.

He said the manufacturing sector recorded the highest number of cases in the workplace cluster category, with 95,156 cases involving 639 clusters.

“Most of the positive cases reported in this workplace cluster category are foreigners, at 100,086 cases (68 per cent) compared with Malaysians, at 46,954 cases (32 per cent),” he said in a statement on the development of the COVID-19 situation today.

Dr Noor Hisham said a lackadaisical attitude in adhering to the standard operating procedures (SOPs), set by the government, was one of the contributors to workplace cluster cases.

He said although the ministry had set various guidelines and SOPs in the workplace, such as physical distancing, limiting the number of employees present in the workplace, etc., the level of awareness of the importance of implementing the SOPs still needed to be improved.

“Everyone, especially employers and employees need to realise that adherence to the guidelines is for their good as well,” he said.

However, he said the continuous effort by employers in conducting screening tests on employees is highly appreciated, as an initial step to curb the spread of infections in the workplace.

Elaborating further, Dr Noor Hisham said according to the records of the Jalan Tiga Salak Cluster in Selangor, involving a factory in Bandar Baru Salak Tinggi Industrial Area in Sepang, reported the highest number of cases, at 873 cases thus far, followed by the Industri Senawang Cluster which recorded 752 cases.

“Next is the Industri Batu Berendam Cluster in Melaka which recorded 641 cases, and the Jalan Padang Tembak Kelantan Cluster, Terengganu with 598 cases,” he said.

In this regard, Dr Noor Hisham said that the enforcement of the SOPs in the workplace should be enhanced as part of efforts to curb COVID-19 infection, especially involving clusters in workplaces.

Source: BERNAMA News Agency

COVID-19 Vaccination Outreach Programme well-received in Negeri Sembilan

— The COVID-19 Vaccination Outreach Programme implemented in Negeri Sembilan, using a Kuala Pilah Dental Clinic trailer is the government’s effort to ensure herd immunity is achieved, including the rural areas.

Kuala Pilah District Disaster Committee chairman Mohd Faizal Abdul Manap said the programme, which began today, is targeting three areas in the district with Felda Kepis becoming the first location following a rise in COVID-19 cases in the area.

”Kuala Pilah was chosen as the first district for the programme due to the increase in cases in the Jalan Seroja cluster, taking the cumulative cases to 127 as of June 11.

“The mobile vaccination centre (PPV) will operate for five days in Felda Kepis, targeting over 1,000 residents before heading to the next destination in Padang Lebar, Seri Menanti focusing on the Orang Asli settlements,” he told reporters after visiting the Dewan Semai Budi Felda Kepis here today.

He added the Health Department will use a mobile clinic as a PPV at Orang Asli villages.

Meanwhile, many Felda Kepis residents, when met by Bernama in the programme, were initially nervousness about getting the first dose because of the phobia of seeing a doctor and fear of needles.

For 61-year-old Salasiah Mat Isa, she said admitted being afraid of receiving the jab but agreed to do so after getting the advice from her children and husband.

“I thought I wanted to run away, but then I braced myself as it was for my own good. This morning, my husband took his first shot. Upon returning home, he said he was not in pain and then she agreed to get the vaccination, ”she said.

Sharing a similar sentiment was a wheel-bound senior citizen, Mohd Arshad Abd Razak, 76, who suffers from a spinal problem who admitted the injection was not painful as he had imagined.

“Thank you to the state government for setting up mobile PPV to facilitate the vaccination exercise for the villagers since the vaccination centres are located 30 kilometres from Felda Kepis,” he said.

He received his first dose with his wife, Miskiah Abdul Rahman, 55, and his two children, Ahmad Salehuddin Mohd Arshad, 40, and Azhad Mohd Arshad. 36.

Source: BERNAMA News Agency